CAR T 细胞疗法：治疗自身免疫性疾病的一种前景广阔的方法。

IF 1.7 4区医学 Q2 PEDIATRICS

Indian pediatrics Pub Date : 2024-10-15 Epub Date: 2024-08-26

Deepshi Thakral, Tejas Ramanan, Narendra Kumar Bagri

引用次数: 0

摘要

嵌合抗原受体（CAR）-T 细胞已成为一种前景广阔的基于免疫效应细胞的疗法。随着治疗血液恶性肿瘤的成果喜人并获得批准，我们将讨论这种新型治疗方式在对传统药物和生物疾病调节药物难治的全身性自身免疫性疾病和免疫介导的炎症性疾病中的应用范围。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

CAR T-Cell Therapy: A Promising Modality for Autoimmune Diseases.

Chimeric Antigen Receptor (CAR) T-cells have emerged as a promising immune effector cell-based therapy. With promising results and approval for the treatment of hematological malignancies, we discuss the scope of this novel therapeutic modality in systemic autoimmune diseases and immune-mediated inflammatory disorders refractory to conventional and biological disease-modifying agents.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Indian pediatrics 医学-小儿科

CiteScore

3.30

自引率

8.70%

发文量

344

审稿时长

3-8 weeks

期刊介绍： The general objective of Indian Pediatrics is "To promote the science and practice of Pediatrics." An important guiding principle has been the simultaneous need to inform, educate and entertain the target audience. The specific key objectives are: -To publish original, relevant, well researched peer reviewed articles on issues related to child health. -To provide continuing education to support informed clinical decisions and research. -To foster responsible and balanced debate on controversial issues that affect child health, including non-clinical areas such as medical education, ethics, law, environment and economics. -To achieve the highest level of ethical medical journalism and to produce a publication that is timely, credible and enjoyable to read.